Immuron (NASDAQ:IMRN) Short Interest Update

Immuron (NASDAQ:IMRN) saw a large growth in short interest during the month of September. As of September 15th, there was short interest totaling 115,685 shares, a growth of 240.2% from the August 31st total of 34,009 shares. Currently, 1.5% of the company’s stock are sold short. Based on an average daily trading volume, of 12,663,789 shares, the short-interest ratio is presently 0.0 days.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Immuron in a report on Monday. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the company presently has an average rating of “Sell”.

Immuron Price Performance

Shares of IMRN traded down $0.03 on Friday, hitting $1.16. 43,882 shares of the stock traded hands, compared to its average volume of 6,531,659. Immuron has a one year low of $0.68 and a one year high of $2.39. The business has a 50 day simple moving average of $1.21 and a 200 day simple moving average of $1.06.

Immuron (NASDAQ:IMRN) last issued its earnings results on Friday, August 14th. The company reported ($0.08) EPS for the quarter. The business had revenue of $1.27 million during the quarter.

Immuron Company Profile

Immuron Limited (NASDAQ: IMRN) is a biopharmaceutical company focused on developing and commercializing orally delivered therapeutics based on highly specific antibodies derived from hyperimmune bovine colostrum. Its approach is designed to target pathogens and disease-related factors within the gastrointestinal tract without requiring systemic absorption.

The company’s leading commercial product is Travelan, an oral antibody-based product intended to help prevent travelers’ diarrhea caused by enterotoxigenic Escherichia coli (ETEC).